History | Tildrakizumab for treating moderate to severe plaque psoriasis | Guidance | NICE

History

Documents created during the development process.

Expected publication

Equality Impact Assessment (Guidance development) (PDF 156 KB)

Published:

17 April 2019

Final draft guidance

Final draft guidance
Final appraisal document (PDF 303 KB)

Published:

08 March 2019
Committee papers (PDF 1.58 MB)

Published:

08 March 2019
Public committee slides (PDF 541 KB)

Published:

08 March 2019

Draft guidance

Draft guidance
Appraisal consultation document (PDF 350 KB)

Published:

04 December 2018
Committee papers (PDF 5.91 MB)

Published:

04 December 2018

Invitation to participate

Final scope (PDF 89 KB)

Published:

14 June 2018
Final matrix (PDF 259 KB)

Published:

14 June 2018
Equality impact assessment (Scoping) (PDF 74 KB)

Published:

14 June 2018
NICE's response to comments on the draft scope and provisional matrix (PDF 370 KB)

Published:

15 June 2018

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

Draft scope pre referral (MSWord 79 KB)

Published:

29 June 2017
Draft matrix pre referral (MSWord 65 KB)

Published:

29 June 2017